The US Centers for Disease Control and Prevention (CDC) has published an alert calling for nirsevimab—a jab given to infants to protect them against severe respiratory syncytial virus (RSV)—to be rationed because of shortages.1The long acting monoclonal antibody was approved in the US in July after evidence showed it reduced the incidence of medically attended RSV related lower respiratory tract infections.In the alert, the CDC said “in the context of limited supply during the 2023-24 RSV season” available 100 mg doses of nirsevimab should be prioritised for infants at the highest risk for severe RSV disease.Vulnerable groups include those under 6 months old and those aged 6 to 8 months in high risk groups, such as American Indian and Alaska Native infants, and those born before 29 weeks gestation.For eligible children aged 8 to 19 months, the CDC has recommended that the previously approved monoclonal antibody palivizumab—a once monthly injection—be…
Source link